Albrecht Graeve - UCB SA Non-Executive Independent Director
UCBJY Stock | USD 58.22 1.22 2.14% |
Director
Mr. Albrecht De Graeve has served as Independent NonExecutive Director of UCB S.A. since April 29, 2010. He is Chairman of the Company Audit Committee, Member of the Audit Committee as of April 29, 2010. He was Chairman of Bekaert NV, Telenet Group Holding NV and Sibelco NV. He became Chief Executive Officer of the Bekaert Group in May 2006. From 2002 until May 2006 he was Chief Financial and Administration Officer and General Secretary of the Group. He started his career in 1980 with Arthur Andersen Co and joined Alcatel Bell in 1982. In 1991 he became General Manager Shanghai Bell Telephone Equipment Mfg. Cy in Shanghai. In 1994 he was appointed Vice President, Director Operations, Alcatel Trade International and later Director International Affairs, Alcatel Alsthom in Paris. In 1996 he became Managing Director of the Flemish Public Radio TV Broadcaster . He holds a Master in Law from the University of Ghent, studied Financial Management at IPO and became Master in Tax Management at VLEKHO since 2010.
Age | 63 |
Tenure | 14 years |
Phone | 32 2 559 99 99 |
Web | https://www.ucb.com |
UCB SA Management Efficiency
The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Terrence Kearney | Vertex Pharmaceuticals | 63 | |
David Altshuler | Vertex Pharmaceuticals | 53 | |
Anne Kverneland | Novo Nordisk AS | 64 | |
David Greenway | Vertex Pharmaceuticals | 34 | |
Joshua Lewis | Pearson PLC ADR | 53 | |
Michael Brown | Regeneron Pharmaceuticals | 77 | |
Bonnie Bassler | Regeneron Pharmaceuticals | 55 | |
Marc TessierLavigne | Regeneron Pharmaceuticals | 58 | |
Harish Manwani | Pearson PLC ADR | 64 | |
Eivind Kolding | Novo Nordisk AS | 55 | |
Lincoln Wallen | Pearson PLC ADR | 60 | |
Graeme Pitkethly | Pearson PLC ADR | 54 | |
Laurence Debroux | Novo Nordisk AS | 51 | |
Stig Stroebaek | Novo Nordisk AS | 55 | |
Joseph Ramelli | Moderna | 47 | |
Sangeeta Bhatia | Vertex Pharmaceuticals | 49 | |
Arthur Ryan | Regeneron Pharmaceuticals | 75 | |
Elaine Ullian | Vertex Pharmaceuticals | 69 | |
Linda Lorimer | Pearson PLC ADR | 68 | |
Michael Lynton | Pearson PLC ADR | 61 | |
Coram Williams | Pearson PLC ADR | 44 |
Management Performance
Return On Equity | 0.11 | |||
Return On Asset | 0.0468 |
UCB SA ADR Leadership Team
Elected by the shareholders, the UCB SA's board of directors comprises two types of representatives: UCB SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UCB. The board's role is to monitor UCB SA's management team and ensure that shareholders' interests are well served. UCB SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UCB SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee | ||
Detlef Thielgen, CFO and Executive VP | ||
Kay Davies, Independent Director | ||
Dirk Teuwen, VP Corporate Societal Responsibility | ||
Anna Richo, Executive VP and General Counsel | ||
Viviane Monges, Independent Non-Executive Director | ||
Gerhard Mayr, Non-Executive Chairman of the Board | ||
Cyril Janssen, Director | ||
Caroline Vancoillie, Chief Functions | ||
Cedric Rijckevorsel, Director | ||
JeanChristophe Tellier, Chairman of the Executive Committee, CEO | ||
Arnoud Calesberg, Non-Executive Director | ||
Mark McDade, COO and Executive VP | ||
Xavier Michel, Vice President and Secretary General | ||
Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee | ||
Bharat Tewarie, Executive Vice President Chief Marketing Officer | ||
Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director | ||
Norman Ornstein, Non-Executive Independent Director | ||
Jeff Wren, Executive Vice President Neurology – Patient Value Unit Head | ||
JeanPierre Kinet, Non-Executive Independent Director | ||
Antje Witte, VP of Investor Relations | ||
Alice Dautry, Independent Director | ||
Sandrine CFA, Ex CFO | ||
Harriet Edelman, Non-Executive Independent Director | ||
Ulf Wiinberg, Independent Director | ||
William Silbey, Exec Counsel | ||
Thomas McKillop, Non-Executive Independent Director | ||
Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee | ||
France Nivelle, VP Global Communication | ||
Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee | ||
Pierre Gurdjian, Independent Director | ||
Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP | ||
Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head | ||
Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board | ||
Iris LoewFriedrich, Executive Vice President Chief Medical Officer | ||
CharlesAntoine Janssen, Non-Executive Director | ||
Pr LowFriedrich, Chief VP | ||
Kirsten LundJurgensen, Ex Solutions | ||
Albrecht Graeve, Non-Executive Independent Director | ||
JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee | ||
Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee |
UCB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is UCB SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.11 | |||
Return On Asset | 0.0468 | |||
Profit Margin | 0.15 % | |||
Operating Margin | 0.19 % | |||
Current Valuation | 16.62 B | |||
Shares Outstanding | 379.92 M | |||
Price To Earning | 17.55 X | |||
Price To Book | 1.55 X | |||
Price To Sales | 2.54 X | |||
Revenue | 5.78 B |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards UCB SA in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, UCB SA's short interest history, or implied volatility extrapolated from UCB SA options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.ABBV | AbbVie Inc | |
HBI | Hanesbrands | |
MIDU | Direxion Daily Mid |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UCB SA ADR. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in inflation. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for UCB Pink Sheet analysis
When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |